← Leaderboards
James Louis Rubenstein
University Of California San Francisco
$5,966,949
Attributed
$7,498,836
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $650K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,498,836 · 5
By mechanism
R01$6,481,214 · 2
K23$635,130 · 1
R21$378,233 · 1
M01$4,259 · 1
Top collaborators
- Myriam Marianne Chaumeil5 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Frank Patrick McCormick$56,513,144
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseLymphomaCentral Nervous System LymphomaBrainTumorResistanceInnovationNon-Hodgkin&AposS LymphomaMediatingMethotrexateSpecimenRefractoryImmunotherapyPathway InteractionsCerebrospinal FluidSignal TransductionMalignant NeoplasmsInvestigationMultidisciplinaryLeadCellsRituximabGenetic
Grant awards (23)
Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma$571,523
R01 · FY2023 · CA · contact PI
Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma$584,054
R01 · FY2022 · CA · contact PI
Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma$613,413
R01 · FY2021 · CA · contact PI
Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma$644,765
R01 · FY2020 · CA · contact PI
Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma$650,020
R01 · FY2019 · CA · contact PI
Recognition and Targeting of CNS Lymphoma by Tumor-Associated Macrophages$370,554
R01 · FY2018 · CA · contact PI
Recognition and Targeting of CNS Lymphoma by Tumor-Associated Macrophages$370,554
R01 · FY2017 · CA · contact PI
Recognition and Targeting of CNS Lymphoma by Tumor-Associated Macrophages$370,554
R01 · FY2016 · CA · contact PI
Recognition and Targeting of CNS Lymphoma by Tumor-Associated Macrophages$370,554
R01 · FY2015 · CA · contact PI
Targeted Therapies in CNS Lymphomas$206,680
R21 · FY2015 · CA · contact PI
Recognition and Targeting of CNS Lymphoma by Tumor-Associated Macrophages$384,229
R01 · FY2014 · CA · contact PI
Targeted Therapies in CNS Lymphomas$171,553
R21 · FY2014 · CA · contact PI
The Role of Interleukin-4 (IL-4) in the Pathogenesis of Non-Hodgkin's Lymphoma$291,356
R01 · FY2013 · CA · contact PI
The Role of Interleukin-4 (IL-4) in the Pathogenesis of Non-Hodgkin's Lymphoma$310,019
R01 · FY2012 · CA · contact PI
The Role of Interleukin-4 (IL-4) in the Pathogenesis of Non-Hodgkin's Lymphoma$310,117
R01 · FY2011 · CA · contact PI
The Role of Interleukin-4 (IL-4) in the Pathogenesis of Non-Hodgkin's Lymphoma$319,743
R01 · FY2010 · CA · contact PI
The Role of Interleukin-4 (IL-4) in the Pathogenesis of Non-Hodgkin's Lymphoma$319,759
R01 · FY2009 · CA · contact PI
Molecular Classification and therapy of CNS Lymphomas$127,026
K23 · FY2008 · CA · contact PI
Molecular Classification and therapy of CNS Lymphomas$127,026
K23 · FY2007 · CA · contact PI
Molecular Classification and therapy of CNS Lymphomas$127,026
K23 · FY2006 · CA · contact PI
Molecular Classification and therapy of CNS Lymphomas$127,026
K23 · FY2005 · CA
Molecular Classification and Therapy of CNS Lymphomas$127,026
K23 · FY2004 · CA
Intrathecal Rituximab in Patients with Recurrent Lymphomatous Meningitis$4,259
M01 · FY2004 · RR